<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zdor</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы здоровья и экологии</journal-title><trans-title-group xml:lang="en"><trans-title>Health and Ecology Issues</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2220-0967</issn><issn pub-type="epub">2708-6011</issn><publisher><publisher-name>Gomel State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51523/2708-6011.2009-6-2-3</article-id><article-id custom-type="elpub" pub-id-type="custom">zdor-813</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>РАК МОЛОЧНОЙ ЖЕЛЕЗЫ: АНАЛИЗ ПРОГНОСТИЧЕСКИХ ПОКАЗАТЕЛЕЙ, ХАРАКТЕРИЗУЮЩИХ КЛИНИЧЕСКОЕ ТЕЧЕНИЕ ЗАБОЛЕВАНИЯ</article-title><trans-title-group xml:lang="en"><trans-title>BREAST CANCER ANALYSIS OF FORECASTING PARAMETERS TYPICAL FOR CLINICAL PICTURE OF THE DISEASE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Надыров</surname><given-names>Э. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nadyrov</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский научно-практический центр радиационной медицины и экологии человека</institution></aff><aff xml:lang="en"><institution>Republican Research Centre of Radiation Medicine and Human Ecology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2009</year></pub-date><volume>0</volume><issue>2</issue><fpage>17</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Надыров Э.А., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Надыров Э.А.</copyright-holder><copyright-holder xml:lang="en">Nadyrov E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.gsmu.by/jour/article/view/813">https://journal.gsmu.by/jour/article/view/813</self-uri><abstract><p>Изучены основные клинико-диагностические показатели при раке молочной железы. Показано, что раннее прогрессирование заболевания (до 3-х лет) определяется размерами опухоли, метастатическим поражением лимфатических узлов, высокой гистологической степенью злокачественности, индексом реакции Score для рецепторов прогестерона. Дополнительными факторами прогноза могут явиться молодой возраст пациентки, объем проведенной операции и локализация опухоли во внутренних квадрантах молочной железы.</p></abstract><trans-abstract xml:lang="en"><p>We study the relationship between major clinical-diagnostic indicators with breast cancer. We show the progression of the disease is characterized by a significant decrease in the number of correlations between the clinical diagnostic and immunogistochemical characteristics of tumor tissue.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>прогрессия заболевания</kwd><kwd>клинические и диагностические маркеры</kwd><kwd>breast cancer</kwd><kwd>disease progression</kwd><kwd>clinical and diagnostic markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Семиглазов, В. Ф. Значение прогностических и предстказывающих факторов при выборе леяения у больных метастатическим раком молочной железы / В. Ф. Семиглазов // Практическая онкология. - 2000. - № 2. - С. 26-30.</mixed-citation><mixed-citation xml:lang="en">Семиглазов, В. Ф. Значение прогностических и предстказывающих факторов при выборе леяения у больных метастатическим раком молочной железы / В. Ф. Семиглазов // Практическая онкология. - 2000. - № 2. - С. 26-30.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Steroid hormone receptors as prognostic ondicators in primary breast cancer / S. M. Thorpe [et al.] // Breast Cancer Res Treat. - 1986. - № 7. - Р. 91-98.</mixed-citation><mixed-citation xml:lang="en">Steroid hormone receptors as prognostic ondicators in primary breast cancer / S. M. Thorpe [et al.] // Breast Cancer Res Treat. - 1986. - № 7. - Р. 91-98.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy / T. Petit [et al.] // Eur J Cancer. - 2004. - № 40 (2). - Р. 205-211.</mixed-citation><mixed-citation xml:lang="en">Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy / T. Petit [et al.] // Eur J Cancer. - 2004. - № 40 (2). - Р. 205-211.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Летягин, В. П. Органосохраняющие операции в комплексном лечении больных раком молочной железы / В. П. Летягин, Н. Н. Волченко // Рос. онкол. журн. - 2001. - № 4. - С. 4-6.</mixed-citation><mixed-citation xml:lang="en">Летягин, В. П. Органосохраняющие операции в комплексном лечении больных раком молочной железы / В. П. Летягин, Н. Н. Волченко // Рос. онкол. журн. - 2001. - № 4. - С. 4-6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy / T. Petit [et al.] // Eur. J. Cancer. - 2004. - Vol. 40 (2). - P. 205-211.</mixed-citation><mixed-citation xml:lang="en">Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy / T. Petit [et al.] // Eur. J. Cancer. - 2004. - Vol. 40 (2). - P. 205-211.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dinshaw, K. A. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy / K. A. Dinshaw, A. N. Budrukkar, R. F. Chinoy // Int. J. Radiat. Oncol. Biol. Phys. - 2005. - Vol. 63, № 4. - P. 1132-1141.</mixed-citation><mixed-citation xml:lang="en">Dinshaw, K. A. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy / K. A. Dinshaw, A. N. Budrukkar, R. F. Chinoy // Int. J. Radiat. Oncol. Biol. Phys. - 2005. - Vol. 63, № 4. - P. 1132-1141.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy / P. T. Truong [et al.] // J. Am. Coll. Surg. - 2005. - Vol. 200, № 6. - P. 912-921.</mixed-citation><mixed-citation xml:lang="en">Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy / P. T. Truong [et al.] // J. Am. Coll. Surg. - 2005. - Vol. 200, № 6. - P. 912-921.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases / V-J. Bardou [et al.] // J. Clin. Oncol. - 2003. - Vol. 21. - P. 1973-1979.</mixed-citation><mixed-citation xml:lang="en">Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases / V-J. Bardou [et al.] // J. Clin. Oncol. - 2003. - Vol. 21. - P. 1973-1979.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Estrogen receptor positive (ER+), progesterone receptor negative (PgR-) breast cancer: new insights into molecular mechanisms and clinical implications / G. Arpino [et al.] // Breast cancer research and treatment. 27Ih Annual San Antonio Breast Cancer Symposium. - 2004. - Vol. 88. - Р. 105.</mixed-citation><mixed-citation xml:lang="en">Estrogen receptor positive (ER+), progesterone receptor negative (PgR-) breast cancer: new insights into molecular mechanisms and clinical implications / G. Arpino [et al.] // Breast cancer research and treatment. 27Ih Annual San Antonio Breast Cancer Symposium. - 2004. - Vol. 88. - Р. 105.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hamilton, A. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2 / A. Hamilton, M. Piccart // Ann. Oncol. - 2000. - Vol. 11 (6). - P. 647-663.</mixed-citation><mixed-citation xml:lang="en">Hamilton, A. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2 / A. Hamilton, M. Piccart // Ann. Oncol. - 2000. - Vol. 11 (6). - P. 647-663.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer / A. A. Langerod [et al.] // Breast Cancer Res. - 2007. - № 9 (3). - Р. 30.</mixed-citation><mixed-citation xml:lang="en">TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer / A. A. Langerod [et al.] // Breast Cancer Res. - 2007. - № 9 (3). - Р. 30.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer / J. Lee [et al.] // Cancer Chemother. Pharmacol. - 2008. - № 61 (4). - Р. 569-577.</mixed-citation><mixed-citation xml:lang="en">Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer / J. Lee [et al.] // Cancer Chemother. Pharmacol. - 2008. - № 61 (4). - Р. 569-577.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Рroliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy / A. Vincent-Salomon [et al.] // Eur. J. Cancer. - 2004. - № 40 (10). - Р. 1502-1508.</mixed-citation><mixed-citation xml:lang="en">Рroliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy / A. Vincent-Salomon [et al.] // Eur. J. Cancer. - 2004. - № 40 (10). - Р. 1502-1508.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Боровиков, В. STATISTICA. Искусство анализа данных на компьютере: для профессионалов / В. Боровиков. - 2-е изд. (+ CD). - СПб.: Питер, 2003. - 688 с.</mixed-citation><mixed-citation xml:lang="en">Боровиков, В. STATISTICA. Искусство анализа данных на компьютере: для профессионалов / В. Боровиков. - 2-е изд. (+ CD). - СПб.: Питер, 2003. - 688 с.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffney, D. K. Diminished Survival in Patients With Inner Versus Outer Quadrant Breast Cancers / D. K. Gaffney, A. Tsodikov, C. L.Wiggins // J. Clin. Oncol. 2003. - № 21. - Р. 467-472.</mixed-citation><mixed-citation xml:lang="en">Gaffney, D. K. Diminished Survival in Patients With Inner Versus Outer Quadrant Breast Cancers / D. K. Gaffney, A. Tsodikov, C. L.Wiggins // J. Clin. Oncol. 2003. - № 21. - Р. 467-472.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is «young»? / J. L. Oh. [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2006. - Vol. 65, № 5. - P. 1345-1352.</mixed-citation><mixed-citation xml:lang="en">The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is «young»? / J. L. Oh. [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2006. - Vol. 65, № 5. - P. 1345-1352.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
